TIENAM

This brand name is authorized in Brazil, Cyprus, Estonia, France, Hong Kong SAR China, Japan, Lithuania, Malta, Mexico, Singapore, South Africa, Turkey.

Active ingredients

The drug TIENAM contains a combination of these active pharmaceutical ingredients (APIs):

1	Imipemide UNII 71OTZ9ZE0A - IMIPENEM
	Imipenem is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium Streptomyces cattleya. Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
	Read more about Imipemide
2	Cilastatin UNII 141A6AMN38 - CILASTATIN
	Read more about Cilastatin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DH51	Imipenem and enzyme inhibitor	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DH Carbapenems
Discover more medicines within J01DH51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	525502206151317
EE	Ravimiamet	1331345, 1331356, 1624205
FR	Base de données publique des médicaments	69552232
HK	Department of Health Drug Office	28979
JP	医薬品医療機器総合機構	6139501D2105, 6139501E2038, 6139501G1067
LT	Valstybinė vaistų kontrolės tarnyba	1033350, 1033351, 1066700
MT	Medicines Authority	AA565/77801
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	180M87
SG	Health Sciences Authority	00706P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699636260104, 8699636260111
ZA	Health Products Regulatory Authority	S/20.1.1/175